Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Allarity Therapeutics, Inc. (ALLR : NSDQ)
 
 • Company Description   
Allarity Therapeutics Inc. is a clinical-stage biopharmaceutical company. It involved in developing novel oncology therapeutics together with drug-specific DRP(R) companion diagnostics for personalized cancer care. Allarity Therapeutics Inc. is based in Cambridge, MA U.S.A.

Number of Employees: 7

 
 • Price / Volume Information   
Yesterday's Closing Price: $1.01 Daily Weekly Monthly
20 Day Moving Average: 385,274 shares
Shares Outstanding: 15.08 (millions)
Market Capitalization: $15.23 (millions)
Beta: 0.04
52 Week High: $7.45
52 Week Low: $0.61
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 19.37% 14.07%
12 Week 38.13% 17.98%
Year To Date -13.68% -19.14%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
24 SCHOOL ST. 2ND FLOOR
-
BOSTON,MA 02108
USA
ph: 401-426-4664
fax: -
investorrelations@allarity.com http://www.allarity.com
 
 • General Corporate Information   
Officers
Thomas H. Jensen - Chief Executive Officer and Director
Gerald W. McLaughlin - Chairman of the Board
Alexander Epshinsky - Chief Financial Officer
Joseph W. Vazzano - Director
Laura E. Benjamin - Director

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 016744500
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/25
Next Expected EPS Date: 08/04/25
Share - Related Items
Shares Outstanding: 15.08
Most Recent Split Date: 9.00 (0.03:1)
Beta: 0.04
Market Capitalization: $15.23 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-46.85 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/04/25  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 0.92
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: 99.96%
vs. Previous Quarter: -%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
06/30/25 - -
03/31/25 - -147.94
12/31/24 - -267.71
ROA
06/30/25 - -
03/31/25 - -90.33
12/31/24 - -114.18
Current Ratio
06/30/25 - -
03/31/25 - 2.66
12/31/24 - 2.06
Quick Ratio
06/30/25 - -
03/31/25 - 2.66
12/31/24 - 2.06
Operating Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -
Net Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -
Pre-Tax Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -
Book Value
06/30/25 - -
03/31/25 - 1.09
12/31/24 - 1.62
Inventory Turnover
06/30/25 - -
03/31/25 - -
12/31/24 - -
Debt-to-Equity
06/30/25 - -
03/31/25 - 0.00
12/31/24 - 0.00
Debt-to-Capital
06/30/25 - -
03/31/25 - 0.00
12/31/24 - 0.00
 

Powered by Zacks Investment Research ©